Details

Autor(en) / Beteiligte

• Kasamatsu, Tetsuhiro
• Hashimoto, Nao
• Sakaya, Nao
• Awata-Shiraiwa, Maaya
• Ishihara, Rei
• Murakami, Yuki
• Masuda, Yuta
• Gotoh, Nanami
• Nagai, Kazue
• Oda, Tsukasa
• Yokohama, Akihiko
• Saitoh, Takayuki
• Handa, Hiroshi
• Tsukamoto, Norifumi
• Hayashi, Kunihiko
• Murakami, Hirokazu

Titel

IDO2 rs10109853 polymorphism affects the susceptibility to multiple myeloma

Ist Teil von

• Clinical and experimental medicine, 2021-05, Vol.21 (2), p.323-329

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Single-nucleotide polymorphisms (SNPs) of the IDO1 and IDO2 genes have been associated with some diseases. Here, we investigated the association of IDO1 and IDO2 SNPs with the susceptibility to multiple myeloma (MM) and their relationships with MM clinical features. We obtained genomic DNA from 100 patients with MM and 149 healthy race-matched controls and determined IDO1 promoter − 1849G/T (rs3824259) and IDO2 R248W (rs10109853) genotypes by using the polymerase chain reaction–restriction fragment length polymorphism method. The patients with MM had a significantly higher frequency of the IDO2 R248W RR genotype (high-activity type) (59.0% vs. 43.6%, odds ratio = 1.86, 95% confidence interval = 1.11–3.11, P  = 0.017) compared with those in healthy controls. Patients with the IDO2 R248W RR genotype (high-activity type) were significantly younger and had a significantly lower frequency of International Staging System (ISS) stage III condition than those with the RW and WW genotypes (median 63 years vs. 69 years, P  = 0.025; 15 [25.4%] vs. 50 [48.8%]). In addition, the IDO2 R248W RR genotype was significantly associated with a higher level of hemoglobin at diagnosis (mean ± standard deviation, 10.7 ± 2.36 vs. 9.27 ± 2.40 g/dL; P  = 0.0032). Neither polymorphism significantly affected overall survival. Our study indicates that IDO2 R248W may be associated with the susceptibility to MM and severity of anemia.